>

MEETINGS / EVENTS

RSS

May 05 - 07 2014, 12:00 AM - 12:00 AM

2014 ASA Legislative Conference

>

FDA MEDWATCH ALERTS

March 28, 2014

FDA Update on the Shortage of Normal Saline

Summary:

FDA Update on the Shortage of Normal Saline

March 18, 2014

FDA MedWatch - Merit Medical Systems, Custom Procedural Trays/Kits Containing 1 percent Lidocaine HCl Injection, 10mg/mL: Recall - Particulates Found in Hospira supplied Lidocaine

Summary:

Merit Medical Systems Custom Procedural Trays Kits Recall Particulates Found in Hospira Lidocaine

March 18, 2014

McKesson Technologies Anesthesia Care: Recall - Patient Case Data May Not Match Patient Data

Summary:

McKesson Technologies Anesthesia Care Recall Patient Case Data May Not Match Patient Data

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

Study Finds Potential Link Between Morphine-Like Chemicals or Drugs and Breast Cancer

Chicago — (March 21, 2012) 

A new study in the April issue of Anesthesiology analyzed inherited (genetic) differences in how the body responds to its own morphine-like chemicals and pain-relieving opioid drugs, and whether they influence breast cancer survival. Preclinical animal studies have suggested that opioids may promote tumor growth.

“Many are unaware that the human body produces its own morphine-like chemicals every day,” said senior study author Samuel McLean, M.D. “Therefore, if morphine-like chemicals influence cancer survival, then naturally occurring inherited differences in how the body responds to its own morphine-like chemicals and pain-relieving opioid drugs also should be associated with cancer survival.”

More than 2,000 women with breast cancer were included in the study. The authors assessed six naturally occurring genetic variations which might influence the body's response to morphine-like chemicals. In particular, the well-known A118G variation in the mu-opioid receptor gene was assessed. Genotyping was performed to examine the association between these variations and breast cancer survival.

Findings showed that the patient genotype A118G was associated with breast cancer-specific mortality at 10 years. Women with one or more copies of the G variant had decreased breast cancer-specific mortality. The results suggest that opioid pathways may be involved in tumor growth. Further studies are needed to examine how genetic variants influencing opioid system function may relate to cancer survival.

“Our hope is that other researchers can perform studies similar to ours, with their own patient data, to see if they obtain similar results,” said study co-investigator Andrey Bortsov, M.D., Ph.D. “If so, then this would increase the likelihood that this is a true finding. If opioid systems influence tumor growth, then this could open up new opportunities for treating cancer using relatively non-toxic treatments.”

For more information, visit the Anesthesiology website at www.anesthesiology.org.

THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 50,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring that physician anesthesiologists evaluate and supervise the medical care of patients before, during, and after surgery to provide the highest quality and safest care that every patient deserves.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/WhenSecondsCount. Join the ANESTHESIOLOGYTM 2013 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES2013.

###

Contact:

American Society of Anesthesiologists
communications@asahq.org
847-825-5586